Zhejiang Starry Pharmaceutical Co.,Ltd.

Total Valuation

Zhejiang Starry Pharmaceutical Co.,Ltd. carries a market capitalization of 4.24B, placing it among publicly traded companies globally. Its enterprise value stands at 6.88B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Zhejiang Starry Pharmaceutical Co.,Ltd. currently has 438.41M shares outstanding.

Valuation Ratios

Zhejiang Starry Pharmaceutical Co.,Ltd. trades at a trailing price-to-earnings ratio of 53.50. The price-to-sales ratio is 1.94, and the price-to-book ratio stands at 5.78.

Enterprise Valuation

On an enterprise value basis, Zhejiang Starry Pharmaceutical Co.,Ltd. trades at an EV/EBITDA multiple of 86.29 and an EV/FCF ratio of 12.64. The EV/Sales ratio of 2.85 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 86.29 provides insight into valuation relative to core operating earnings.

Financial Position

Zhejiang Starry Pharmaceutical Co.,Ltd. maintains a current ratio of 0.89, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 99.51, indicating elevated leverage, while an interest coverage ratio of 0.89 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Zhejiang Starry Pharmaceutical Co.,Ltd. has paid -2.93M in income taxes, reflecting an effective tax rate of 45.67.

Stock Price Statistics

Zhejiang Starry Pharmaceutical Co.,Ltd.'s stock has declined approximately -2.4218% over the past 52 weeks. The 50-day moving average sits at 10.99, while the 200-day moving average is 10.55.

Income Statement

Over the trailing twelve months, Zhejiang Starry Pharmaceutical Co.,Ltd. generated 2.42B in revenue and converted that into -42.86M in net income, yielding earnings per share of -0.09. EBITDA reached 79.72M, while operating income came in at 79.72M.

Balance Sheet

Zhejiang Starry Pharmaceutical Co.,Ltd. holds 433.05M in cash and equivalents against 2.62B in total debt, resulting in a net debt position of 1.85B. Total book value stands at 810.81M, with working capital of -249.99M providing operational flexibility.

Cash Flow

After subtracting -460.51M in capital expenditures, free cash flow totaled -460.51M - equivalent to -0.96 per share.

Margins

Zhejiang Starry Pharmaceutical Co.,Ltd. operates with a gross margin of 18.66, reflecting its pricing power and cost economics. The operating margin of 3.30 and net profit margin of -1.77 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of -386.23 indicates the proportion of earnings distributed to shareholders.

Stock Splits

Zhejiang Starry Pharmaceutical Co.,Ltd.'s most recent stock split took place on June 17, 2022 with a 5:7 split ratio.

Scores

Zhejiang Starry Pharmaceutical Co.,Ltd. posts an Altman Z-Score of 1.41, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.